Zentalis Pharma gains as FDA lifts partial clinical hold on cancer drug studies

Zentalis Pharmaceuticals

16/09/2024 12:48

** Shares of drug developer Zentalis Pharmaceuticals
 ZNTL.O  rise 45.68% to $4.72 premarket
    ** Co says U.S. FDA has lifted the partial clinical hold on
studies of azenosertib, its experimental cancer drug
    ** In June, FDA placed three studies on partial clinical
hold following the death of two trial participants
    ** FDA has cleared the way for resumption in enrollment for
all ongoing studies, with no changes in the development plan; co
resume activities as quickly as possible
    ** Azenosertib is currently being studied as monotherapy and
combination studies in ovarian cancer and additional tumor types
    ** Up to last close, stock down ~79% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))